LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This trial is designed to examine the hypothesis that thoracoscopic LAA clipping is superior
to NOACs for stroke, systemic embolism, all-cause mortality, major bleeding events and
clinically relevant nonmajor bleeding events in AF patients at high risk of embolism
(CHA2DS2-VASc ≥2 in men and ≥3 in women) that are not undergoing ablation.